Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300

Nyheten uppdaterades 2013-06-24 12:23

Paris, France – June 22, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY)
announced today that the first phase 3 study results (EDITION I) for its
investigational new insulin U300 showed equivalent blood sugar control with
fewer night-time low blood sugar events compared to Lantus® (insulin
glargine [rDNA origin] injection). The company also announced topline…

Källa: Mynewsdesk news release

Lämna gärna en kommentar